These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 27856123)

  • 1. Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.
    Sunakawa Y; Ichikawa W; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Nakajima T
    Clin Colorectal Cancer; 2017 Sep; 16(3):e171-e180. PubMed ID: 27856123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer.
    Aljehani MA; Morgan JW; Guthrie LA; Jabo B; Ramadan M; Bahjri K; Lum SS; Selleck M; Reeves ME; Garberoglio C; Senthil M
    JAMA Surg; 2018 Jan; 153(1):60-67. PubMed ID: 28975237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy.
    Takada S; Sagawa T; Fujikawa K; Tahatsu K; Fukai Y; Hashishita H; Takahashi Y; Endo M
    Asian Pac J Cancer Prev; 2018 Aug; 19(8):2325-2330. PubMed ID: 30141310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial.
    von Einem JC; Heinemann V; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Decker T; Klein S; Held S; Jung A; Kirchner T; Haas M; Holch J; Michl M; Aubele P; Boeck S; Schulz C; Giessen C; Stintzing S; Modest DP
    J Cancer Res Clin Oncol; 2014 Sep; 140(9):1607-14. PubMed ID: 24816724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.
    Price T; Shen L; Ma B; Esser R; Chen W; Gibbs P; Lim R; Cheng AL
    Asia Pac J Clin Oncol; 2019 Aug; 15(4):225-230. PubMed ID: 31090260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary tumor location as a prognostic factor in metastatic colorectal cancer.
    Loupakis F; Yang D; Yau L; Feng S; Cremolini C; Zhang W; Maus MK; Antoniotti C; Langer C; Scherer SJ; Müller T; Hurwitz HI; Saltz L; Falcone A; Lenz HJ
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25713148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05).
    Tsuji A; Sunakawa Y; Ichikawa W; Nakamura M; Kochi M; Denda T; Yamaguchi T; Shimada K; Takagane A; Tani S; Kotaka M; Kuramochi H; Furushima K; Koike J; Yonemura Y; Takeuchi M; Fujii M; Nakajima T
    Target Oncol; 2016 Dec; 11(6):799-806. PubMed ID: 27306648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.
    Douillard JY; Zemelka T; Fountzilas G; Barone C; Schlichting M; Heighway J; Eggleton SP; Srimuninnimit V
    Clin Colorectal Cancer; 2014 Mar; 13(1):14-26.e1. PubMed ID: 24370353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
    Snyder M; Bottiglieri S; Almhanna K
    Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of primary tumor side on clinical outcomes of first-line cetuximab plus FOLFOX-4 in
    Qin S; Liu T; Xu J; Li Q; Cheng Y; Zhang A; Esser R; Chang H; Li J
    Future Oncol; 2023 May; 19(15):1053-1061. PubMed ID: 37017100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer.
    Yamaguchi T; Iwasa S; Nagashima K; Ikezawa N; Hamaguchi T; Shoji H; Honma Y; Takashima A; Okita N; Kato K; Yamada Y; Shimada Y
    Anticancer Res; 2016 Jul; 36(7):3531-6. PubMed ID: 27354619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour location and efficacy of first-line EGFR inhibitors in
    Benavides M; Díaz-Rubio E; Carrato A; Abad A; Guillén C; Garcia-Alfonso P; Gil S; Cano MT; Safont MJ; Gravalos C; Manzano JL; Sánchez A; Alcaide J; López R; Massutí B; Sastre J; Martínez E; Escudero P; Méndez M; Aranda E
    ESMO Open; 2019; 4(6):e000599. PubMed ID: 31803504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: superior progression-free survival is restricted to patients with measurable tumors and objective tumor response--a retrospective study.
    Yang YH; Lin JK; Chen WS; Lin TC; Yang SH; Jiang JK; Lan YT; Lin CC; Yen CC; Tzeng CH; Teng HW
    J Cancer Res Clin Oncol; 2014 Nov; 140(11):1927-36. PubMed ID: 24934725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.
    Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
    Clin Colorectal Cancer; 2018 Sep; 17(3):170-178.e3. PubMed ID: 29627309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study.
    Yu Y; Ying J; Zhang W; Li W; Sun Y; Yang L; Cui C; Zeng Y; Zhou A
    Asia Pac J Clin Oncol; 2019 Jun; 15(3):128-135. PubMed ID: 30693649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.
    Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
    Ann Oncol; 2017 Aug; 28(8):1862-1868. PubMed ID: 28449055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
    Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.